Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Open Label, Multi-centre, Phase III Study to Investigate the Efficacy of Bendamustine Compared to Treatment of Physician's Choice in the Treatment of Subjects With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab

NCT01289223 is registered in ClinicalTrials.gov with Mundipharma Research Limited as lead sponsor.

NCT NCT01289223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01289223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Open Label, Multi-centre, Phase III Study to Investigate the Efficacy of Bendamustine Compared to Treatment of Physician's Choice in the Treatment of Subjects With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab
Lead sponsor
Mundipharma Research Limited
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2011
Completion date
July 31, 2018
Enrollment
88 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

indolent b-cell nhl